Single-Dose Infliximab in Hepatitis C Genotype 1 Treatmentnaive Patients with High Serum Levels of Tumour Necrosis Factor-Alpha Does Not Influence the Efficacy of Pegylated Interferon Alpha-2B/Ribavirin Therapy | Zendy

Curtis Cooper | Zendy; Stephen D. Shafran | Zendy; Susan Greenbloom | Zendy; Robert Enns | Zendy; John Farley | Zendy; Nir Hilzenrat | Zendy; K. Williams | Zendy; Magdy Elkashab | Zendy; Nabil Abadir | Zendy; Manuela G. Neuman | Zendy

Open Access

Single-Dose Infliximab in Hepatitis C Genotype 1 Treatmentnaive Patients with High Serum Levels of Tumour Necrosis Factor-Alpha Does Not Influence the Efficacy of Pegylated Interferon Alpha-2B/Ribavirin Therapy

Author(s) -

Curtis Cooper,

Stephen D. Shafran,

Susan Greenbloom,

Robert Enns,

John Farley,

Nir Hilzenrat,

K. Williams,

Magdy Elkashab,

Nabil Abadir,

Manuela G. Neuman

Publication year - 2014

Publication title -

canadian journal of gastroenterology and hepatology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.921

H-Index - 65

eISSN - 2291-2797

pISSN - 2291-2789

DOI - 10.1155/2014/367131

Subject(s) - medicine , ribavirin , infliximab , gastroenterology , pegylated interferon , adverse effect , hepatitis c virus , hepatitis c , immunology , tumor necrosis factor alpha , virus

Serum tumour necrosis factor-alpha (TNF-α) levels correlate negatively with hepatitis C virus (HCV) antiviral response.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research